Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


28.11.2022

1 Am J Pathol
1 Biochem Biophys Res Commun
3 BMC Cancer
5 BMC Gastroenterol
2 Cancer
1 Endoscopy
1 Eur Radiol
5 Gastroenterology
1 Gastrointest Endosc
1 J Gastroenterol Hepatol
14 J Hepatol
1 J Pediatr Surg
3 PLoS One
1 Pol J Radiol
1 Proc Natl Acad Sci U S A
1 Radiologia (Engl Ed)
5 Radiology
3 Transplant Proc


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. SAPONARA E, Penno C, Orsini V, Wang ZY, et al
    Loss of Hepatic Lgr4 and Lgr5 Promotes Nonalcoholic Fatty Liver Disease.
    Am J Pathol. 2022 Nov 18:S0002-9440(22)00358.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. ZHAO Q
    Mutant IDH1 attenuates hepatic lipogenesis through PTEN dependent pathway.
    Biochem Biophys Res Commun. 2022;637:254-258.
    PubMed         Abstract available


    BMC Cancer

  3. CHEN X, Wang Y, Liu H, Zhang J, et al
    CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinbeta1.
    BMC Cancer. 2022;22:1200.
    PubMed         Abstract available

  4. YEH TL, Hsu MS, Hsu HY, Tsai MC, et al
    Risk of cardiovascular diseases in cancer patients: A nationwide representative cohort study in Taiwan.
    BMC Cancer. 2022;22:1198.
    PubMed         Abstract available

  5. MALIK IA, Rajput M, Werner R, Fey D, et al
    Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer.
    BMC Cancer. 2022;22:1193.
    PubMed         Abstract available


    BMC Gastroenterol

  6. ZHANG X, Zhang X, Liu M, Zhu L, et al
    Global, regional, and national burden of cirrhosis and other chronic liver diseases due to alcohol use, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019.
    BMC Gastroenterol. 2022;22:484.
    PubMed         Abstract available

  7. SATO S, Kawai H, Sato S, Iwasaki H, et al
    Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease.
    BMC Gastroenterol. 2022;22:478.
    PubMed         Abstract available

  8. WU HY, Chang CC, Yeh CC, Chen MY, et al
    Adverse outcomes after non-hepatic surgeries in patients with alcoholic liver diseases: a propensity-score matched study.
    BMC Gastroenterol. 2022;22:475.
    PubMed         Abstract available

  9. LU H, Zheng C, Xiong B, Xia X, et al
    Efficacy and safety of heparin plus dexamethasone after partial splenic embolization for liver cirrhosis with massive splenomegaly.
    BMC Gastroenterol. 2022;22:470.
    PubMed         Abstract available

  10. LIU Q, Zhao G, Li Q, Wu W, et al
    A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
    BMC Gastroenterol. 2022;22:471.
    PubMed         Abstract available


    Cancer

  11. NAKAGAWA M, Inoue M, Ogasawara S, Maruta S, et al
    Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Cancer. 2022 Nov 24. doi: 10.1002/cncr.34559.
    PubMed         Abstract available

  12. ZHENG Y, Huang N, Kuang S, Zhang J, et al
    The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery.
    Cancer. 2022 Nov 26. doi: 10.1002/cncr.34552.
    PubMed         Abstract available


    Endoscopy

  13. KATAYAMA T, Nakamura K, Arahata K, Takarabe S, et al
    Successful reintervention using dual-channel endoscope for perforation by partially migrated stent after endoscopic ultrasound-guided hepaticogastrostomy.
    Endoscopy. 2022 Nov 25. doi: 10.1055/a-1968-7086.
    PubMed        


    Eur Radiol

  14. MARUZZELLI L, D'Amico M, Tuzzolino F, Petridis I, et al
    Clinical outcomes of transjugular intrahepatic portosystemic shunt with PTFE-covered stents after liver transplantation and technical results in split and whole liver graft recipients.
    Eur Radiol. 2022 Nov 23. doi: 10.1007/s00330-022-09259.
    PubMed         Abstract available


    Gastroenterology

  15. MURILLO PEREZ CF, Fisher H, Hiu S, Kareithi D, et al
    Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
    Gastroenterology. 2022 Sep 13. pii: S0016-5085(22)01060.
    PubMed         Abstract available

  16. YEOH BS, Saha P, Golonka RM, Zou J, et al
    Enterohepatic Shunt-Driven Cholemia Predisposes to Liver Cancer.
    Gastroenterology. 2022;163:1658-1671.
    PubMed         Abstract available

  17. ZHU Y, Shi H, He S
    An Unusual Cause of Gastric Variceal Bleeding.
    Gastroenterology. 2022;163:1502-1504.
    PubMed        

  18. ROBBINS J, El Hassan I, Siebenburgen C
    Evaluation and Treatment of GI Bleeding in a 51-Year-Old Man.
    Gastroenterology. 2022;163:1498-1501.
    PubMed        

  19. OH AR, Jeong Y, Yu J, Minh Tam DT, et al
    Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization.
    Gastroenterology. 2022 Nov 16:S0016-5085(22)01295.
    PubMed         Abstract available


    Gastrointest Endosc

  20. OTANI K, Shimada S, Watanabe T, Nadatani Y, et al
    Long-term rebleeding rate and predictive factors of rebleeding after capsule endoscopy in patients with obscure GI bleeding.
    Gastrointest Endosc. 2022;96:956-969.
    PubMed         Abstract available


    J Gastroenterol Hepatol

  21. HAKODA H, Kiritani S, Kokudo T, Yoshimura K, et al
    Probe electrospray ionization mass spectrometry-based rapid diagnosis of liver tumors.
    J Gastroenterol Hepatol. 2022;37:2182-2188.
    PubMed         Abstract available


    J Hepatol

  22. CHOLANKERIL G, Kramer JR, Chu J, Yu X, et al
    Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03299-8. doi: 10.1016/j.jhep.2022.
    PubMed         Abstract available

  23. LUO L, Yao X, Yang W
    Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
    PubMed        

  24. CHOI SJ, Choi SH, Kim DW, Kwag M, et al
    Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03297-4. doi: 10.1016/j.jhep.2022.
    PubMed         Abstract available

  25. AJMERA V, Cepin S, Tesfai K, Hofflich H, et al
    A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    J Hepatol. 2022 Nov 18:S0168-8278(22)03302-5. doi: 10.1016/j.jhep.2022.
    PubMed         Abstract available

  26. LOUVET A, Bourcier V, Archambeaud I, d'Alteroche L, et al
    Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort.
    J Hepatol. 2022 Nov 21:S0168-8278(22)03304-9. doi: 10.1016/j.jhep.2022.
    PubMed         Abstract available

  27. NAHON P, Bamba-Funck J, Layese R, Trepo E, et al
    Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
    J Hepatol. 2022 Nov 22:S0168-8278(22)03294-9. doi: 10.1016/j.jhep.2022.
    PubMed         Abstract available

  28. CORPECHOT C, Carrat F, Gaouar F, Chau F, et al
    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00411.
    PubMed         Abstract available

  29. KIM BK, Tamaki N, Imajo K, Yoneda M, et al
    Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
    J Hepatol. 2022;77:1482-1490.
    PubMed         Abstract available

  30. TIAN C, Min X, Zhao Y, Wang Y, et al
    MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM.
    J Hepatol. 2022;77:1491-1503.
    PubMed         Abstract available

  31. BRANDEL V, Schimek V, Gober S, Hammond T, et al
    Hepatectomy-induced apoptotic extracellular vesicles stimulate neutrophils to secrete regenerative growth factors.
    J Hepatol. 2022;77:1619-1630.
    PubMed         Abstract available

  32. MENDEZ-SANCHEZ N, Pal SC
    New terms for fatty liver disease other than MAFLD: Time for a reality check.
    J Hepatol. 2022;77:1716-1717.
    PubMed        

  33. PAFILI K, Kahl S, Mastrototaro L, Strassburger K, et al
    Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease.
    J Hepatol. 2022;77:1504-1514.
    PubMed         Abstract available

  34. MITTEN EK, Baffy G
    Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;77:1642-1656.
    PubMed         Abstract available

  35. RUMGAY H, Arnold M, Ferlay J, Lesi O, et al
    Global burden of primary liver cancer in 2020 and predictions to 2040.
    J Hepatol. 2022;77:1598-1606.
    PubMed         Abstract available


    J Pediatr Surg

  36. WANG K, Dong C, Sun C, Zheng W, et al
    Treatments and outcomes of intra-operative portal vein thrombosis in living-donor liver transplantation due to biliary atresia.
    J Pediatr Surg. 2022 Jun 22. pii: S0022-3468(22)00430.
    PubMed         Abstract available


    PLoS One

  37. DENK A, Muller K, Schlosser S, Heissner K, et al
    Liver diseases as a novel risk factor for delirium in the ICU-Delirium and hepatic encephalopathy are two distinct entities.
    PLoS One. 2022;17:e0276914.
    PubMed         Abstract available

  38. TEERASARNTIPAN T, Thanapirom K, Chirapongsathorn S, Suttichaimongkol T, et al
    Validation of prognostic scores predicting mortality in acute liver decompensation or acute-on-chronic liver failure: A Thailand multicenter study.
    PLoS One. 2022;17:e0277959.
    PubMed         Abstract available

  39. TATEDA T, Iino C, Sasada T, Sato S, et al
    Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study.
    PLoS One. 2022;17:e0277930.
    PubMed         Abstract available


    Pol J Radiol

  40. BARAKAT MMK, Awadallah SM, Madkour SS
    The role of three different contrast-enhanced, abbreviated MRI protocols as a screening tool of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
    Pol J Radiol. 2022;87:e574-e583.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  41. OSBORN LJ, Schultz K, Massey W, DeLucia B, et al
    A gut microbial metabolite of dietary polyphenols reverses obesity-driven hepatic steatosis.
    Proc Natl Acad Sci U S A. 2022;119:e2202934119.
    PubMed         Abstract available


    Radiologia (Engl Ed)

  42. VARELA-PONTE R, Martinez-Lago N, Vieito-Villar M, Martin Carreira-Villamor J, et al
    Impact of risk factors on the efficacy and complications of ultrasound-guided percutaneous liver biopsy of space-occupying lesions.
    Radiologia (Engl Ed). 2022;64:497-505.
    PubMed         Abstract available


    Radiology

  43. ZHANG W, Huang C, Yin T, Miao X, et al
    Ultrasensitive US Microvessel Imaging of Hepatic Microcirculation in the Cirrhotic Rat Liver.
    Radiology. 2022 Nov 22:220739. doi: 10.1148/radiol.220739.
    PubMed         Abstract available

  44. DUAN L, Zhang B, Zheng X
    Restratification of Advanced Hepatocellular Carcinoma to Identify Patients Sensitive to Transarterial Chemoembolization.
    Radiology. 2022;305:E73.
    PubMed        

  45. WU W, Jing X, Xue GQ, Zhu XL, et al
    A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions.
    Radiology. 2022;305:721-728.
    PubMed         Abstract available

  46. SENDUR HN, Cerit MN
    Reliable Assessment of US Performance for Liver Fat Quantification.
    Radiology. 2022;305:E70.
    PubMed        

  47. WEAR KA, Han A, Rubin JM, Gao J, et al
    US Backscatter for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative.
    Radiology. 2022 Oct 18:220606. doi: 10.1148/radiol.220606.
    PubMed         Abstract available


    Transplant Proc

  48. NAGY G, Gerlei Z, Haboub-Sandil A, Gorog D, et al
    Optimizing Survival for Hepatocellular Carcinoma After Liver Transplantation: A Single-Center Report and Current Perspectives.
    Transplant Proc. 2022 Nov 19:S0041-1345(22)00718.
    PubMed         Abstract available

  49. OBANA A, Sato Y
    Autologous Partial Liver Transplantation for a Symptomatic Giant Hepatic Hemangioma. A Case Report.
    Transplant Proc. 2022 Nov 17:S0041-1345(22)00690.
    PubMed        

  50. CHEN CC, Chang WC, Lin SH
    Mycophenolate-Induced Hepatotoxicity Precipitates Tacrolimus Nephrotoxicity in a Kidney Transplant Recipient: A Case Report.
    Transplant Proc. 2022 Nov 9. pii: S0041-1345(22)00695.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: